Effects of the Dopamine D2 Allosteric Modulator, PAOPA, on the Expression of GRK2, Arrestin-3, ERK1/2, and on Receptor Internalization

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Basu, Dipannita ^a   Tian, Yuxin ^a   Bhandari, Jayant ^a   Jiang, Jian Ru ^a   Hui, Patricia ^a   Johnson, Rodney L ^b   Mishra, Ram K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[(PYRROLIDINYLCARBONYL)AMINO] 2 OXO 1 PYRROLIDINEACETAMIDE; ARRESTIN 3; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR KINASE 2; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; QUINPIROLE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ALLOSTERIC REGULATION; ANIMALS; ARRESTINS; CELLS, CULTURED; G-PROTEIN-COUPLED RECEPTOR KINASE 2; GENE EXPRESSION; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTEIN TRANSPORT; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2;

EID: 84881189216     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070736     Document Type: Article

References (63)

1. Christopoulos A, Kenakin T, (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374. doi:10.1124/pr.54.2.323. PubMed: 12037145.
2. Conn PJ, Christopoulos A, Lindsley CW, (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8: 41-54. doi:10.1038/nrd2760. PubMed: 19116626.
3. Keov P, Sexton PM, Christopoulos A, (2011) Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60: 24-35. doi:10.1016/j.neuropharm.2010.07.010. PubMed: 20637785.
4. May LT, Leach K, Sexton PM, Christopoulos A, (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47: 1-51. doi:10.1146/annurev.pharmtox.47.120505.105159. PubMed: 17009927.
5. Christopoulos A, (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1: 198-210. doi:10.1038/nrd746. PubMed: 12120504.
6. Baures PW, Pradhan A, Ojala WH, Gleason WB, Mishra RK, et al. (1999) Synthesis and dopamine receptor modulating activity of unsubstituted and substituted triproline analogues of L-prolyl-L-leucyl-glycinamide (PLG). Bioorg Med Chem Lett 9: 2349-2352. doi:10.1016/S0960-894X(99)00386-8. PubMed: 10476867.
7. Bhagwanth S, Mishra S, Daya R, Mah J, Mishra RK, et al. (2012) Transformation of Pro-Leu-Gly-NH(2) peptidomimetic positive allosteric modulators of the dopamine D(2) receptor into negative modulators. Acs Chem Neurosci 3: 274-284. doi:10.1021/cn200096u. PubMed: 22860194.
8. Bhagwanth S, Mishra RK, Johnson RL, (2013) Development of peptidomimetic ligands of Pro-Leu-Gly-NH(2) as allosteric modulators of the dopamine D(2) receptor. Beilstein J Org Chem 9: 204-214. doi:10.3762/bjoc.9.24. PubMed: 23400263.
9. Dolbeare K, Pontoriero GF, Gupta SK, Mishra RK, Johnson RL, (2003) Synthesis and dopamine receptor modulating activity of 3-substituted gamma-lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide. J Med Chem 46: 727-733. doi:10.1021/jm020441o. PubMed: 12593653.
10. Evans MC, Pradhan A, Venkatraman S, Ojala WH, Gleason WB, et al. (1999) Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring alpha,alpha-disubstituted amino acids. J Med Chem 42: 1441-1447. doi:10.1021/jm980656r. PubMed: 10212130.
11. Fisher A, Mann A, Verma V, Thomas N, Mishra RK, et al. (2006) Design and synthesis of photoaffinity-labeling ligands of the L-prolyl-L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor. J Med Chem 49: 307-317. doi:10.1021/jm050644n. PubMed: 16392815.
12. Genin MJ, Mishra RK, Johnson RL, (1993) Dopamine receptor modulation by a highly rigid spiro bicyclic peptidomimetic of Pro-Leu-Gly-NH2. J Med Chem 36: 3481-3483. doi:10.1021/jm00074a032. PubMed: 7901418.
13. Johnson RL, Bontems RJ, Yang KE, Mishra RK, (1990) Synthesis and biological evaluation of analogues of Pro-Leu-Gly-NH2 modified at the leucyl residue. J Med Chem 33: 1828-1832. doi:10.1021/jm00168a045. PubMed: 1971310.
14. Khalil EM, Pradhan A, Ojala WH, Gleason WB, Mishra RK, et al. (1999) Synthesis and dopamine receptor modulating activity of substituted bicyclic thiazolidine lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide. J Med Chem 42: 2977-2987. doi:10.1021/jm990140n. PubMed: 10425107.
15. Mishra RK, Srivastava LK, Johnson RL, (1990) Modulation of high-affinity CNS dopamine D2 receptor by L-pro-L-leu-glycinamide (PLG) analogue 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide. Prog Neuropsychopharmacol Biol Psychiatry 14: 821-827. doi:10.1016/0278-5846(90)90054-K. PubMed: 1981396.
16. Raghavan B, Skoblenick KJ, Bhagwanth S, Argintaru N, Mishra RK, et al. (2009) Allosteric modulation of the dopamine D2 receptor by Pro-Leu-Gly-NH2 peptidomimetics constrained in either a polyproline II helix or a type II beta-turn conformation. J Med Chem 52: 2043-2051. doi:10.1021/jm801575w. PubMed: 19271750.
17. Sreenivasan U, Mishra RK, Johnson RL, (1993) Synthesis and dopamine receptor modulating activity of lactam conformationally constrained analogues of Pro-Leu-Gly-NH2. J Med Chem 36: 256-263. doi:10.1021/jm00054a010. PubMed: 8093736.
18. Subasinghe NL, Bontems RJ, McIntee E, Mishra RK, Johnson RL, (1993) Bicyclic thiazolidine lactam peptidomimetics of the dopamine receptor modulating peptide Pro-Leu-Gly-NH2. J Med Chem 36: 2356-2361. doi:10.1021/jm00068a013. PubMed: 8103113.
19. Vartak AP, Skoblenick K, Thomas N, Mishra RK, Johnson RL, (2007) Allosteric modulation of the dopamine receptor by conformationally constrained type VI beta-turn peptidomimetics of Pro-Leu-Gly-NH2. J Med Chem 50: 6725-6729. doi:10.1021/jm070895r. PubMed: 18052024.
20. Levey AI, Hersch SM, Rye DB, Sunahara RK, Niznik HB, et al. (1993) Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci U S A 90: 8861-8865. doi:10.1073/pnas.90.19.8861. PubMed: 8415621.
21. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG, (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189-225. PubMed: 9457173.
22. Vallone D, Picetti R, Borrelli E, (2000) Structure and function of dopamine receptors. Neurosci Biobehav Rev 24: 125-132. doi:10.1016/S0149-7634(99)00063-9. PubMed: 10654668.
23. Howes OD, Kapur S, (2009) The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull 35: 549-562. doi:10.1093/schbul/sbp006. PubMed: 19325164.
24. Verma V, Mann A, Costain W, Pontoriero G, Castellano JM, et al. (2005) Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog. J Pharmacol Exp Ther 315: 1228-1236. doi:10.1124/jpet.105.091256. PubMed: 16126839.
25. Yu KL, Rajakumar G, Srivastava LK, Mishra RK, Johnson RL, (1988) Dopamine receptor modulation by conformationally constrained analogues of Pro-Leu-Gly-NH2. J Med Chem 31: 1430-1436. doi:10.1021/jm00402a031. PubMed: 3385734.
26. Beyaert MG, Daya RP, Dyck BA, Johnson RL, Mishra RK, (2013) PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia. Eur Neuropsychopharmacol 23: 253-262. doi:10.1016/j.euroneuro.2012.04.010. PubMed: 22658400.
27. Dyck B, Guest K, Sookram C, Basu D, Johnson R, et al. (2011) PAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms in schizophrenia. Schizophr Res 125: 88-92. doi:10.1016/j.schres.2010.09.025. PubMed: 21036015.
28. Mann A, Verma V, Basu D, Skoblenick KJ, Beyaert MG, et al. (2010) Specific binding of photoaffinity-labeling peptidomimetics of Pro-Leu-Gly-NH2 to the dopamine D2L receptor: evidence for the allosteric modulation of the dopamine receptor. Eur J Pharmacol 641: 96-101. doi:10.1016/j.ejphar.2010.05.018. PubMed: 20639138.
29. Ito K, Haga T, Lameh J, Sadée W, (1999) Sequestration of dopamine D2 receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5. Eur J Biochem 260: 112-119. doi:10.1046/j.1432-1327.1999.00125.x. PubMed: 10091590.
30. Skinbjerg M, Ariano MA, Thorsell A, Heilig M, Halldin C, et al. (2009) Arrestin3 mediates D(2) dopamine receptor internalization. Synapse 63: 621-624. doi:10.1002/syn.20636. PubMed: 19309759.
31. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG, (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27: 107-144. doi:10.1146/annurev.neuro.27.070203.144206. PubMed: 15217328.
32. Pereira A, Sugiharto-Winarno A, Zhang B, Malcolm P, Fink G, et al. (2012) Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs. Int J Neuropsychopharmacol 15: 1149-1160. doi:10.1017/S1461145711001404. PubMed: 21943960.
33. Pereira A, Fink G, Sundram S, (2009) Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor. J Mol Neurosci 39: 185-198. doi:10.1007/s12031-009-9188-5. PubMed: 19277491.
34. Ahmed MR, Gurevich VV, Dalby KN, Benovic JL, Gurevich EV, (2008) Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. J Pharmacol Exp Ther 325: 276-283. doi:10.1124/jpet.107.131987. PubMed: 18178904.
35. Bychkov ER, Ahmed MR, Gurevich VV, Benovic JL, Gurevich EV, (2011) Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder. Neurobiol Dis 44: 248-258. doi:10.1016/j.nbd.2011.07.009. PubMed: 21784156.
36. Chong VZ, Young LT, Mishra RK, (2002) cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment. J Neurochem 82: 1533-1539. doi:10.1046/j.1471-4159.2002.01104.x. PubMed: 12354301.
37. Guo N, Guo W, Kralikova M, Jiang M, Schieren I, et al. (2010) Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers. Neuropsychopharmacology 35: 806-817. doi:10.1038/npp.2009.189. PubMed: 19956086.
38. Kim KM, Valenzano KJ, Robinson SR, Yao WD, Barak LS, et al. (2001) Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J Biol Chem 276: 37409-37414. doi:10.1074/jbc.M106728200. PubMed: 11473130.
39. Namkung Y, Dipace C, Javitch JA, Sibley DR, (2009) G protein-coupled receptor kinase-mediated phosphorylation regulates post-endocytic trafficking of the D2 dopamine receptor. J Biol Chem 284: 15038-15051. doi:10.1074/jbc.M900388200. PubMed: 19332542.
40. Iwata K, Ito K, Fukuzaki A, Inaki K, Haga T, (1999) Dynamin and rab5 regulate GRK2-dependent internalization of dopamine D2 receptors. Eur J Biochem 263: 596-602. doi:10.1046/j.1432-1327.1999.00549.x. PubMed: 10406971.
41. Zahniser NR, Dubocovich ML, (1983) Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum. J Pharmacol Exp Ther 227: 592-599. PubMed: 6655559.
42. Jaworski JN, Gonzales RA, Randall PK, (2001) Effect of dopamine D2/D3 receptor antagonist sulpiride on amphetamine-induced changes in striatal extracellular dopamine. Eur J Pharmacol 418: 201-206. doi:10.1016/S0014-2999(01)00936-0. PubMed: 11343690.
43. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK, (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69: 483-510. doi:10.1146/annurev.physiol.69.022405.154749. PubMed: 17305471.
44. Shenoy SK, Lefkowitz RJ, (2003) Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 375: 503-515. doi:10.1042/BJ20031076. PubMed: 12959637.
45. Welsh GI, Hall DA, Warnes A, Strange PG, Proud CG, (1998) Activation of microtubule-associated protein kinase (Erk) and p70 S6 kinase by D2 dopamine receptors. J Neurochem 70: 2139-2146. PubMed: 9572301.
46. Suhara T, Sudo Y, Okauchi T, Maeda J, Kawabe K, et al. (1999) Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. Int J Neuropsychopharmacol 2: 73-82. doi:10.1017/S1461145799001431. PubMed: 11281973.
47. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, et al. (1997) Limbic selectivity of clozapine. Lancet 350: 490-491. doi:10.1016/S0140-6736(05)63078-4. PubMed: 9274589.
48. Kornhuber J, Brücke T, Angelberger P, Asenbaum S, Podreka I, (1995) SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain. J Neural Transm Gen Sect 101: 95-103. doi:10.1007/BF01271548. PubMed: 8695060.
49. Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ, (1998) Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation 98: 1783-1789. doi:10.1161/01.CIR.98.17.1783. PubMed: 9788834.
50. Luo Y, Kokkonen GC, Wang X, Neve KA, Roth GS, (1998) D2 dopamine receptors stimulate mitogenesis through pertussis toxin-sensitive G proteins and Ras-involved ERK and SAP/JNK pathways in rat C6-D2L glioma cells. J Neurochem 71: 980-990. PubMed: 9721723.
51. Welsh GI, Hall DA, Warnes A, Strange PG, Proud CG, (1998) Activation of microtubule-associated protein kinase (Erk) and p70 S6 kinase by D2 dopamine receptors. J Neurochem 70: 2139-2146. PubMed: 9572301.
52. Cai G, Zhen X, Uryu K, Friedman E, (2000) Activation of extracellular signal-regulated protein kinases is associated with a sensitized locomotor response to D(2) dopamine receptor stimulation in unilateral 6-hydroxydopamine-lesioned rats. J Neurosci 20: 1849-1857. PubMed: 10684886.
53. Premont RT, Gainetdinov RR, (2007) Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 69: 511-534. doi:10.1146/annurev.physiol.69.022405.154731. PubMed: 17305472.
54. Kim KM, Valenzano KJ, Robinson SR, Yao WD, Barak LS, et al. (2001) Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J Biol Chem 276: 37409-37414. doi:10.1074/jbc.M106728200. PubMed: 11473130.
55. Salim S, Standifer KM, Eikenburg DC, (2007) Extracellular signal-regulated kinase 1/2-mediated transcriptional regulation of G-protein-coupled receptor kinase 3 expression in neuronal cells. J Pharmacol Exp Ther 321: 51-59. doi:10.1124/jpet.106.116921. PubMed: 17255468.
56. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, et al. (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122: 261-273. doi:10.1016/j.cell.2005.05.012. PubMed: 16051150.
57. Mishra RK, Marcotte ER, Chugh A, Barlas C, Whan D, et al. (1997) Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG). Peptides 18: 1209-1215. doi:10.1016/S0196-9781(97)00147-2. PubMed: 9396063.
58. Castellano JM, Batrynchuk J, Dolbeare K, Verma V, Mann A, et al. (2007) MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Peptides 28: 2009-2015. doi:10.1016/j.peptides.2007.07.026. PubMed: 17766011.
59. Namkung Y, Sibley DR, (2004) Protein kinase C mediates phosphorylation, desensitization, and trafficking of the D2 dopamine receptor. J Biol Chem 279: 49533-49541. doi:10.1074/jbc.M408319200. PubMed: 15347675.
60. Thibault D, Albert PR, Pineyro G, Trudeau LE, (2011) Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism. J Biol Chem 286: 9174-9184. doi:10.1074/jbc.M110.166454. PubMed: 21233215.
61. Freedman NJ, Lefkowitz RJ, (1996) Desensitization of G protein-coupled receptors. Recent Prog Horm Res 51: 319-351. PubMed: 8701085.
62. Konradi C, Heckers S, (2001) Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 50: 729-742. doi:10.1016/S0006-3223(01)01267-7. PubMed: 11720691.
63. Harrison PJ, Weinberger DR, (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10: 40-68. doi:10.1038/sj.mp.4001558. PubMed: 15263907.